Century Therapeutics, Inc. (IPSC)
- Previous Close
3.1500 - Open
3.2200 - Bid 2.8000 x 100
- Ask 2.9400 x 100
- Day's Range
2.8200 - 3.2500 - 52 Week Range
1.2800 - 5.5100 - Volume
160,996 - Avg. Volume
215,955 - Market Cap (intraday)
186.676M - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.83
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
www.centurytx.comRecent News: IPSC
Performance Overview: IPSC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPSC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPSC
Valuation Measures
Market Cap
186.68M
Enterprise Value
62.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
76.43
Price/Book (mrq)
1.01
Enterprise Value/Revenue
27.79
Enterprise Value/EBITDA
-0.51
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.47%
Return on Equity (ttm)
-56.07%
Revenue (ttm)
2.23M
Net Income Avi to Common (ttm)
-136.67M
Diluted EPS (ttm)
-2.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
172.74M
Total Debt/Equity (mrq)
26.07%
Levered Free Cash Flow (ttm)
-71.09M